Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2009 1
2011 3
2012 1
2016 1
2017 1
2020 1
2021 9
2022 8
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Pioneering a paradigm shift in tissue engineering and regeneration with polysaccharides and proteins-based scaffolds: A comprehensive review.
Angolkar M, Paramshetti S, Gahtani RM, Al Shahrani M, Hani U, Talath S, Osmani RAM, Spandana A, Gangadharappa HV, Gundawar R. Angolkar M, et al. Among authors: al shahrani m. Int J Biol Macromol. 2024 Apr;265(Pt 1):130643. doi: 10.1016/j.ijbiomac.2024.130643. Epub 2024 Mar 11. Int J Biol Macromol. 2024. PMID: 38467225 Review.
High-throughput computational screening and in vitro evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR-HER2 dual inhibitor in gastric tumors.
Shahrani MA, Gahtani R, Abohassan M, Alshahrani M, Alraey Y, Dera A, Asiri MR, Rajagopalan P. Shahrani MA, et al. Oncol Res. 2023 Dec 28;32(2):251-259. doi: 10.32604/or.2023.043139. eCollection 2023. Oncol Res. 2023. PMID: 38186572 Free PMC article.
Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the AblT315I mutant kinase to combat imatinib resistance in chronic myeloid leukemia.
Al Shahrani M, Gahtani RM, Abohassan M, Alasmari S, Makkawi M. Al Shahrani M, et al. Med Oncol. 2023 Oct 3;40(11):316. doi: 10.1007/s12032-023-02182-8. Med Oncol. 2023. PMID: 37789230
Mitochondrial dysfunction is a key pathological driver of early stage Parkinson's.
Toomey CE, Heywood WE, Evans JR, Lachica J, Pressey SN, Foti SC, Al Shahrani M, D'Sa K, Hargreaves IP, Heales S, Orford M, Troakes C, Attems J, Gelpi E, Palkovits M, Lashley T, Gentleman SM, Revesz T, Mills K, Gandhi S. Toomey CE, et al. Among authors: al shahrani m. Acta Neuropathol Commun. 2022 Sep 8;10(1):134. doi: 10.1186/s40478-022-01424-6. Acta Neuropathol Commun. 2022. PMID: 36076304 Free PMC article.
29 results